Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 - ...

As a young lawyer, Mohandas Gandhi wasn’t especially interested in politics—until 1894, when a law set out to disenfranchise ...

XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx ...

Teachers can help students build their capacity to stay on task by ensuring that they have a clear path to start working, ...

Laconia High School celebrated their top 10 students Wednesday night, led by Valedictorian Ava Noyes, who engineering and ...

A young lady celebrated completing her English and Literature studies at University of Ibadan. She was denied admission into law two times from different schools.

With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of ...

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.14862. Operator ...

The Relist Watch column examines cert petitions that the Supreme Court has “relisted” for its upcoming conference. A short explanation of relists is available here. There are 261 petitions and ...

The Central Board of Secondary Education has announced the schedule for submitting the List of Candidates for the Class 10 ...

On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate ...